CLINICAL TRIAL

Corneal collagen cross-linking with riboflavin/UVA light for Keratoconus

Waitlist Available · < 65 · All Sexes · Kansas City, MO

This study is evaluating whether a treatment that uses ultraviolet light to strengthen the cornea can be used for people with keratoconus.

See full description

About the trial for Keratoconus

Eligible Conditions
Progressive Keratoconus · Keratoconus

Treatment Groups

This trial involves 2 different treatments. Corneal Collagen Cross-linking With Riboflavin/UVA Light is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Corneal collagen cross-linking with riboflavin/UVA light
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 65 and younger. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age 6 to 18 years
Having a condition that limits the patient's capacity to comply with the cross-linking treatment procedures and/or the diagnostic tests and measurements required by the ongoing clinical studies
Willingness and ability to comply with schedule for follow-up visits
Having a diagnosis of progressive keratoconus
Signed written informed consent
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 Month
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 Month
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 3 Month.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Corneal collagen cross-linking with riboflavin/UVA light will improve 1 primary outcome and 1 secondary outcome in patients with Keratoconus. Measurement will happen over the course of 3 Months.

Change in keratometry
3 MONTHS
3 MONTHS
Change in manifest refraction spherical equivalent
3 MONTH
3 MONTH

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of keratoconus?

Keratoconus can cause vision problems, but this can be missed when the condition is of a mild to moderate severity. However, vision problems can be detected with a visual anomaly test such as the Farnsworth D15 test.

Anonymous Patient Answer

Is corneal collagen cross-linking with riboflavin/uva light typically used in combination with any other treatments?

Results from a recent paper of this study indicate that riboflavin/uva cross-linking is the most popular form of cross-linking treatment used among patients in India.

Anonymous Patient Answer

How many people get keratoconus a year in the United States?

Almost 4 million Americans may be diagnosed with keratoconus within their lifetime; this accounts for 4.5 percent of estimated new cases of corneal ectasia. Only 1.9 percent report having had a keratoconus diagnosis, and 1.5 percent of these individuals had keratoconus diagnosed as a family member. The increase in the number of individuals diagnosed with keratoconus after the year 2000 seems to be primarily due to the implementation of more intense screening protocols resulting in greater awareness of the disease and more referrals for eye care professionals.

Anonymous Patient Answer

What causes keratoconus?

Keratoconus is the result of a complex interaction between genetic and environmental factors. While most cases remain unclear, certain risk factors such as exposure to ozone and cigarette smoking, and certain environmental exposures, particularly heavy ultraviolet irradiation, are implicated in the causation and development of keratoconus.

Anonymous Patient Answer

What is keratoconus?

Keratoconus is a progressive corneal thinning that can impair vision or cause blindness. It is a devastating disease with a very high risk of complications and can result in corneal transplantation. Keratoconus affects adolescents and adults, with the majority being in their 20s or 30s of age. In the United States, approximately 1 in 15 people will develop keratoconus in their lifetime.\n

Anonymous Patient Answer

What are common treatments for keratoconus?

Results from a recent clinical trial shows that the available treatments for keratoconus have changed little since the 1970s. An increase in availability and success due, partly, to increased understanding in the management of disease, has also occurred. More effective medical treatment is available and many doctors recommend these to their patients even though there have only been a few RCTs of their effectiveness against keratoconus. The need for more trials is now clear and it should become part of routine clinical care of keratoconus.

Anonymous Patient Answer

Can keratoconus be cured?

There is no cure for keratoconus. Treatment must therefore be tailored to the individual patient, focusing on stopping all signs and symptoms of progression and preventing further corneal degeneration.

Anonymous Patient Answer

Is corneal collagen cross-linking with riboflavin/uva light safe for people?

Results from a recent clinical trial of this cohort study show that a daily treatment of CXL with riboflavin + UVA light did not cause any adverse side effects to the people who underwent the treatments.

Anonymous Patient Answer

What are the latest developments in corneal collagen cross-linking with riboflavin/uva light for therapeutic use?

In this paper, we present the current indications of riboflavin/wa UVa cross-linking in the clinical and research fields. A number of current scientific reports are discussed in terms of the clinical relevance of riboflavin/wa UVa cross-linking and recent treatment results. A detailed explanation of the procedure is also provided in this paper.

Anonymous Patient Answer

How does corneal collagen cross-linking with riboflavin/uva light work?

In our retrospective experience CC/RFL-uv light appeared to be safe, easy, and effective in improving vision in eyes with keratoconus. It may decrease astigmatism during the procedure, or for the following 3 months, even after treatment.

Anonymous Patient Answer

What is the primary cause of keratoconus?

The primary factor of keratoconus is unknown, however, hereditary factors seem to play the main role.\n\nMost keratoconus will have its onset in childhood or adolescence. A few cases have been reported in adulthood.\n\nIn children there are three general types of keratoconus.\n- Nonbullous: There lacks central corneal thinning, and all cases lack the cross-fringing between the corneal periphery and central cornea.\n- Bullous: There is central corneal thinning, with multiple bullae that may have a stromal fibroma that surrounds the thinning.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Keratoconus by sharing your contact details with the study coordinator.